Novartis will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant Narasimhan said ...
This report from Towards Healthcare, a sister firm of Precedence Research, provides a comprehensive analysis of the upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback